Skip to main content

Advertisement

Table 2 KRAS status as a predictive marker in lung cancer

From: KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

Reference Patients tested for KRAS Patients by KRAS status Treatment arm Endpoint KRAS-mut KRAS-wt
KRAS-mut KRAS-wt
Rodenhius et al., 1997 [68] 62 (stage III-IV) 16 46 Carboplatin + ifosfamide + etoposide ORR (%) 19 26
PFS (months) 4 5
OS (months) 8 9
Schiller et al., 2001 [69] 184 (stage II-IIIA) 44 140 Cisplatin + etoposide OS (months) 24.7 42
Eberhard et al., 2005 [70] 133 (advanced stage) 25 108 Carboplatin + paclitaxel + erlotinib ORR (%) 23 26
PFS (months) 6.0 5.4
OS (months) 13.5 11.3
Tsao et al., 2007 [71] 210 (stage Ib-II) 46 164 Vinorelbine + cisplatin OS (months) 6.4 NR
Mao et al., 2010 [76] 1470 (stage NS) 231 1239 EGFR TKI ORR (%) 3 26
Khambata-Ford et al., 2010 [82] 202 (stage IIIB, IV) 35 167 Taxane + carboplatin + cetuximab ORR (%) 30.8 32.9
PFS (months) 5.6 5.1
OS (months) 16.8 9.7
O’Byrne KJ et al., 2011 [83] 395 (stage IIIB, IV) 75 320 Cisplatin + vinorelbine + cetuximab ORR (%) 36.8 37.3
PFS (months) 5.4 4.4
OS (months) 8.9 11.4
Ludovini V et al., 2011 [79] 166 (stage III, IV) 11 151 EGFR TKI ORR (%) 0 35.7
PFS (months) 2.7 5.6
OS (months) 19.3 28.6
Metro et al., 2012 [81] 67 (stage IIIB-IV) 18 49 EGFR TKI (gefitinib or erlotinib) PFS (months) 1.6 3.0
OS (months) 6.0 21.0
Fiala O et al., 2013 [80] 448 (stage IIIB, IV) 138 (G12C mutation: 38) 410 EGFR TKI PFS (weeks) 4.3 (G12C) vs 9.0 (non-G12C)
OS (weeks) 12.1 (G12C) vs 9.3 (non-G12C)
Zer et al., 2016 [63] 785 (stage IIIB-IV) 155 630 EGFR TKI (pooled analysis) OS (months) 4.5 6.0
Hames ML et al., 2016 [73] 150 (stage IV) 80 70 Conventional chemotherapy PFS (months) 4.5 5.7
OS (months) 8.8 13.5
Dong ZY et al., 2017 [84] 34 (not specified) 8 26 Pembrolizumab ORR (%) 25 6.6
20 (not specified) 5 15 Pembrolizumab or nivolumab PFS (months) 14.7 3.5